Kardigan is a patient-driven cardiovascular drug developer that applies science, data, and technology to move treatments beyond symptom management toward functional cures. Its late-stage portfolio currently centers on three complementary candidates: danicamtiv, a cardiac myosin activator for genetic dilated cardiomyopathy; tonlamarsen, an angiotensinogen-targeted therapy for acute severe hypertension; and ataciguat, an oral soluble guanylate cyclase activator for calcific aortic valve stenosis. By matching critical disease drivers with responders identified in trials, the company aims to deliver multiple medicines in rapid succession, with the first clinical data readouts expected in 2026. Kardigan positions itself as a capital-efficient organization intent on redefining cardiovascular therapeutic innovation. Proceeds from its recent financing will fund the advancement of these late-stage assets through pivotal studies. The company operates from South San Francisco, California, and Princeton, New Jersey. Financial metrics beyond capital raised have not been disclosed.

Total raised

$554M

Funding rounds

2

Latest round

Series B

Latest activity

Oct 2025